- ICPT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $68.8 million.
- ICPT is up 2.2% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ICPT with the Ticky from Trade-Ideas. See the FREE profile for ICPT NOW at Trade-Ideas More details on ICPT: Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. Currently there are 5 analysts that rate Intercept Pharmaceuticals a buy, 1 analyst rates it a sell, and 1 rates it a hold. The average volume for Intercept Pharmaceuticals has been 489,000 shares per day over the past 30 days. Intercept has a market cap of $3.1 billion and is part of the health care sector and drugs industry. The stock has a beta of -6.09 and a short float of 21.7% with 4.36 days to cover. Shares are up 94.8% year-to-date as of the close of trading on Monday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.